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Abstract
Background: The gibbon ape leukemia virus (GaLV) Env protein mediates entry into a wide range of human cells
and is frequently used to pseudotype retroviral vectors. However, an incompatibility exists between GaLV Env and
lentiviral vectors that results in decreased steady-state levels of the mature GaLV Env in cells and prevents its
incorporation into lentiviral vector particles.
Results: We identified the HIV-1 Vpu protein as the major cause of the depletion in GaLV Env levels that occurs
when lentiviral vector components are present. This activity of Vpu targeted the mature (cleaved) form of the GaLV
Env that exists within or beyond the trans-Golgi. The activity required two conserved phospho-serines in the
cytoplasmic tail of Vpu that are known to recruit b TrCP, a substrate adaptor for an SCF E3 ubiquitin ligase
complex, and could be blocked by mutation of lysine 618 in the GaLV Env tail. Moreover, the Vpu-mediated
decrease of GaLV Env levels was inhibited by the lysosomal inhibitor, bafilomycin A1. Interestingly, this activity of
Vpu was only observed in the presence of other lentiviral vector components.
Conclusions: Similar to the mechanism whereby Vpu targets BST-2/tetherin for degradation, these findings
implicate b-TrCP-mediated ubiquitination and the endo-lysosomal pathway in the degradation of the GaLV Env by
lentiviral vector components. Possibly, the cytoplasmic tail of the GaLV Env contains features that mimic bona fide
targets of Vpu, important to HIV-1 replication. Furthermore, the lack of effect of Vpu on GaLV Env in the absence of
other HIV-1 proteins, suggests that a more complex interaction may exist between Vpu and its target proteins,
with the additional involvement of one or more component(s) of the HIV-1 replication machinery.
Background
Both human immunodeficiency virus type 1 (HIV-1)-
based lentiviral and murine leukemia virus (MuLV)-
based retroviral vectors are used clinically in human
gene therapies. However, lentiviral vectors offer an
advantage over the more widely used retroviral vectors
in their ability to transduce non-dividing cells in a range
of organs [[1-3], reviewed in [4]]. A key feature of both
lentiviral and retroviral vectors is their ability to incor-
porate heterologous fusion proteins [reviewed in [5]], in
particular the broadly-tropic vesicular stomatitis virus
(VSV) G protein [6,7], in a process known as pseudotyp-
ing. This allows user-defined host targeting of these vec-
tors, depending on their downstream purpose.
The Gammaretrovirus gibbon ape leukemia virus
(GaLV) Env protein, which has been shown to use a
sodium-dependent phosphate transporter protein (Pit-1)
as its receptor [8,9], is frequently used to pseudotype
retroviral vectors, due to its broad host range and high
efficiency at transducing certain human cell types
[10,11]. Previously we and others reported that although
the GaLV Env could efficiently pseudotype retroviral
vectors, it was not able to pseudotype lentiviral vectors.
This was in marked contrast to the closely related
amphotropic MuLV Env protein which could efficiently
pseudotype both vector particles [12,13]. This phenom-
enon could be efficiently reversed by either substituting
the cytoplasmic tail of GaLV Env with that from MuLV
Env [12,13], deleting the GaLV Env R-peptide (carboxy-
terminal half of the cytoplasmic domain) [13], or substi-
tuting key residues in the vicinity of the R-peptide clea-
vage site [13,14]. Furthermore, we observed that co-
expression of lentiviral vector components led to
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decreased levels of GaLV Env in cells when compared to
the expression levels observed in the presence of retro-
viral elements [13], suggesting a basis for this
incompatibility
In the present study, we investigated the contribution
of specific lentiviral vector components to the observed
decrease in GaLV Env intracellular levels. Our results
identified a major role for the HIV-1 Vpu protein
which, interestingly, only occurred in the presence of
other lentiviral packaging components. Similarities with
the mechanism whereby Vpu degrades CD4 [15-20] and
BST-2/tetherin [21-23] indicate that the GaLV Env pro-
tein may also contain features that make it a target for
degradation by Vpu.
Results
GaLV TM subunit levels are decreased by lentiviral
packaging constructs expressing HIV-1 accessory proteins
We have previously shown that levels of the GaLV Env
trans-membrane (TM) subunit in cell lysates are
strongly reduced in the presence of the lentiviral packa-
ging plasmid pCMVΔR8.2 (R8.2) and that GaLV Env is
unable to pseudotype lentiviral vector particles [13]. In
contrast, we found that GaLV TM levels were unaf-
fected by expression of the retroviral packaging plasmid
pCgp, and that the GaLV Env was able to efficiently
pseudotype retroviral vectors [13]. The GaLV Env pro-
tein is processed from a polypeptide precursor protein,
Pr85, into SU and TM subunits that remain non-cova-
lently linked in the viral particle [24]. The anti-TM anti-
body used in these studies did not detect Pr85, and in
the absence of an anti-SU antibody, we were unable to
distinguish between an effect of R8.2 co-expression on
GaLV Pr85 stability, Pr85 processing to SU and TM, or
TM stability.
In order to identify the components of the lentiviral
vector system responsible for these effects, we analyzed
GaLV TM levels when lentiviral vectors were generated
by the co-transfection of GaLV Env, a lentiviral vector
transfer plasmid (pHR’-CMVLacZ), and the minimal
lentiviral packaging construct, pCMVΔR8.91 (R8.91).
R8.91 expresses HIV-1 Gag-Pol, Tat and Rev proteins,
but does not express any of the HIV-1 accessory pro-
teins (Vpu, Vif, Vpr or Nef) [25] (Figure 1). In contrast
to the results observed in the presence of R8.2, which
decreased the steady-state GaLV TM levels in trans-
fected cells by approximately 60%, we found that co-
expression of R8.91 had no effect on steady state GaLV
TM levels in cell lysates (Figure 2A). This indicates that
one or more accessory proteins of HIV-1 play a key role
in the observed decrease in GaLV TM levels.
Interestingly, despite the lack of effect of R8.91 on
intracellular GaLV TM levels, analysis of vector particles
harvested from culture supernatants revealed a further
defect in the incorporation of GaLV Env into R8.91 gen-
erated vector particles (Figure 2A). Although some TM
protein could be detected in this fraction, it was present
at considerably lower levels than in retroviral particles
produced under the same conditions; and no mature, R-
peptide cleaved form of the protein was apparent.
Removal of the R peptide from the cytoplasmic tail of
GaLV and MLV Env proteins by retroviral proteases
activates their fusogenic potential and is necessary for
full infectivity [26-28]. As expected, the GaLV Env pseu-
dotyped vectors generated using R8.91 had very low
titers (Figure 2B). As we have previously reported [13],
no GaLV TM was detected in R8.2 derived lentiviral
vector particles, and these vectors gave no titer. Taken
together, these results suggest that two areas of incom-
patibility exist between the GaLV Env and lentiviral vec-
tors. First, the expression of one or more HIV-1
accessory proteins in R8.2 reduces the intracellular
steady-state levels of mature (cleaved) GaLV Env, while
an additional block exists that reduces the incorporation
and subsequent R-peptide processing of GaLV Env in
lentiviral particles, even in the absence of any HIV-1
accessory proteins.
Decrease in GaLV TM levels is mostly mediated by the
HIV-1 Vpu protein
In order to identify which of the HIV-1 accessory pro-
teins expressed from R8.2 was responsible for the
decrease in cellular levels of GaLV TM, we generated
derivatives of R8.2 that were deleted for either Vpu, Nef,
or a combination of the Vif and Vpr proteins, and co-
expressed these plasmids with the lentiviral transfer vec-
tor and the GaLV Env. We found that the loss of Vpu
in construct R8.2ΔVpu (Figure 1) had the greatest effect,
resulting in only a 12% decrease in steady-state GaLV
TM levels compared to the 60% inhibition that resulted
from transfection of R8.2. In contrast, the absence of
the Nef, Vpr or Vif proteins did not significantly stabi-
lize the GaLV TM levels (Figure 3), although we did
observe a consistently small enhancement in TM levels
when Nef was deleted; but, overall, this was not statisti-
cally significant.
To confirm that Vpu was largely responsible for the
effects on TM, we next added back the Vpu ORF into
plasmid R8.91 (Figure 1). Expression of R8.91Vpu led to
a marked decrease in GaLV TM levels, although not
quite as complete as observed with R8.2. This finding
also suggested a minor contribution to Env degradation
from an additional HIV-1 accessory protein(s).
Vpu alone is not sufficient to decrease GaLV TM levels
The ability of the Vpu protein to decrease steady state
levels of GaLV TM was reminiscent of its known role
in removing at least two cellular proteins, CD4 and
BST-2/tetherin, from the cell surface [29,30]. There-
fore, we next examined whether the effect on GaLV
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TM levels could be caused by expression of Vpu alone.
Surprisingly, we observed that the co-transfection of
GaLV Env and a Vpu expression plasmid (CΔEVpu)
had no effect on GaLV TM levels (Figure 4). We noted
that the level of expression of Vpu resulting from plas-
mid CΔEVpu was lower than from R8.2. However, we
consider that this difference in Vpu expression levels is
not likely to be the reason for the differences observed.
This interpretation was based on the finding that the
co-expression of CΔEVpu with R8.2ΔVpu caused
equivalent reductions in TM levels as occurred with
R8.2, despite the lower level of Vpu protein in the
cells. In addition, we also investigated whether trans-
fecting increasing amounts of the CΔEVpu plasmid,
with a corresponding increase in the levels of Vpu,
could reduce GaLV TM levels in the absence of a
packaging plasmid, but we found that this was not the
case (data not shown).
We next examined the consequences of co-expression
of R8.91 and CΔEVpu, and found that this also resulted
in a decrease in TM levels, in contrast to the results
obtained with R8.91 or CΔEVpu alone. However, the
Figure 1 Schematic representation of retroviral (pCgp) and lentiviral (R8.2, R8.2ΔVpu, R8.91 and R8.91Vpu) packaging constructs. All
lentiviral vectors express Gag, Pol, Tat and Rev; inclusion of Vif, Nef, Vpu and Vpr is as indicated (grey boxes).
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more complete effect observed when the full set of HIV-
1 genes was present, in the transfection of either R8.2,
or R8.2ΔVpu plus CΔEVpu, suggests that an additional
role is played by one or more of the other HIV-1 acces-
sory proteins.
Mutation of conserved serine residues in Vpu prevents
the decrease in GaLV TM levels
Vpu targets CD4 for proteasomal degradation though
recruitment of the SCF-E3 ubiquitin ligase complex
[18,20]. Vpu binds to both CD4 and the b-TrCP subunit
of the complex, with the interaction with b-TrCP
requiring a conserved motif in Vpu’s cytoplasmic tail
that contains two phosphoserines (DS52GXXS56) [18,20].
Substitution of these serine residues with asparagine
residues blocks CD4 degradation [15,16]. Recruitment of
b-TrCP by Vpu has also been shown to play a role in
counteracting the host budding restriction factor, BST-
2/tetherin, and promoting either proteasomal [23] or
lysosomal [21,22] degradation. We therefore introduced
serine to asparagine substitutions into the packaging
constructs R8.2 and R8.9.1Vpu, and analyzed their
effects on GaLV TM levels. In both cases we observed
Figure 2 GaLV Env levels and titers of pseudotyped vectors. A. Western blot of a representative experiment showing levels of GaLV TM, HIV-
1 p24, MLV p30 and actin in cell lysates and pelleted supernatants from 293T cells co-transfected with plasmids expressing GaLV Env, together
with pCgp, R8.2, R8.91 or a control (Ctrl.) plasmid, as indicated. Also shown is a quantitative analysis of the steady-state levels of GaLV TM in cell
lysates, made relative to the levels in the presence of control plasmid. Results are mean of three independent experiments. B. Titers of GaLV Env
and VSV G pseudotyped retroviral (pCgp) and lentiviral (R8.2 and R8.91) vectors, as indicated, expressed as transducing units per ml (TU/ml). *
indicates no detectable titer.
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that loss of the serines prevented the Vpu mediated
decrease in GaLV TM levels (Figure 5). This suggests a
role for the SCF-E3 ubiquitin ligase complex and pro-
tein degradation pathways in the reduction of GaLV
TM levels.
Substitution K618R in the GaLV tail confers resistance to
R8.2
We have previously shown that replacement of the cyto-
plasmic tail of GaLV Env with the equivalent domain
from the MuLV Env prevents the decrease in TM levels
resulting from expression of R8.2 [13]. In addition, we
observed that this effect could be achieved by two GaLV
to MuLV substitutions in the tail, K618Q and I619A
[13]. Schubert et al. [19] previously reported that inhibi-
tion of the degradation of CD4 by Vpu occurred follow-
ing the substitution of four lysines to arginines in CD4’s
cytosolic domain, suggesting ubiquitination as a
mechanism. We therefore tested whether the loss of
K618 alone was sufficient to preserve levels of GaLV
TM by generating mutants K618Q and K618R. We
found that the K618R substitution rendered the GaLV
Env fully resistant to the R8.2-mediated decrease, similar
to the results obtained when the whole of the GaLV Env
tail was replaced with that of MuLV in construct GM
(TR). In contrast, the K618Q substitution gave an inter-
mediate phenotype (Figure 6).
The SU subunit, but not the Pr85 precursor of GaLV Env,
is affected by R8.2
The GaLV Env protein is synthesized as an 85 kDa pre-
cursor (Pr85). This precursor protein is glycosylated in
the ER and Golgi compartments into a short-lived 95
kDa intermediate that is present in the medial Golgi
[31], and the protein is finally cleaved in the trans-Golgi
network by a cellular furin protease into the mature SU
(70 kDa) and TM (15 kDa) subunits. SU and TM
remain non-covalently linked and are transported to the
cell surface through the host vesicular transport system
[24]. In an attempt to further understand the effect of
R8.2 on GaLV Env, we investigated the fate of both the
Pr85 and SU proteins in the presence of lentiviral vector
components using a labeled version of the protein con-
taining a FLAG tag at the N-terminus of SU (FGaLV
Env) (Figure 7A). In addition, since the glycosylated
forms of Pr85 and SU are not easily resolved by stan-
dard electrophoresis, we treated cells lysates with Pep-
tide-N-glycosidase F (PNGaseF) in order to distinguish
between the two Env proteins, as previously described
[31,32]. Compared to control cells, we found that the
SU subunit was barely detectable in the presence of
R8.2, and was also significantly reduced by either R8.91
or R8.2ΔVpu, while none of the constructs had any
obvious effect on the Pr85 levels (Figure 7B).
Figure 3 Representative Western blot and quantitative analysis of signal density on blots from three independent experiments
analyzing GaLV TM levels in lysates of 293T cells co-transfected with GaLV Env, pHR’ and indicated derivatives of R8.2 and R8.91.
Immunological detection of cellular HIV-1 p24 and actin levels were included as controls.
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All or most of the carbohydrate chains that are
added to glycoproteins in the ER or early Golgi
become endoglycosidase H (endoH) resistant after pas-
sage through the medial Golgi, due to the action of
cellular mannosidase I1 [33,34]. Bedgood and Stallcup
have previously investigated the pattern of endoH-sen-
sitivity in the closely related MuLV Env protein and
found that the Pr85 precursor is endo H-sensitive,
whereas the 70 kDa SU subunit and the transient 95
kDa intermediate it derives from comprise a mixture
of endoH-sensitive and resistant species [31]. Using
this assay to distinguish between Pr85 and SU, we
found that deglycosylation of the various cell extracts
with endoH yielded a similar pattern for the ratios of
SU:Pr85 as was observed following PGNaseF treatment
(Figure 7B). Specifically, Pr85 levels were unaffected
while SU levels were inhibited by R8.2, and to a lesser
extent by R8.91 or R8.2ΔVpu. Together these data sug-
gest that the GaLV Env is targeted by both a Vpu-
dependent mechanism, conferred by R8.2, as well as a
Vpu- independent mechanism that can be provided by
R8.91, and that both events occur after the SU-TM
cleavage in the trans-Golgi.
Vpu targets GaLV Env for degradation through the
endolysosomal pathway
Lastly, we investigated the mechanism for the decrease
in GaLV SU levels caused by expression of R8.2 or
R8.2ΔVpu (Figure 7B). Treatment of cells with either
the proteasomal inhibitor MG132, or the lysosomal inhi-
bitor bafilomycin A1, revealed that while inhibition of
Figure 4 Representative Western blot and quantitative analysis of signal density on blots from three independent experiments
analyzing GaLV TM levels in lysates of 293T cells co-transfected with GaLV Env, pHR’ and indicated derivatives of R8.2 or R8.91, with
(+) expression of Vpu in trans, from plasmid CΔEvpu. Immunological detection of HIV-1 p24 and actin levels were included as controls.
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proteasomal degradation had no effect, SU levels were
restored by treatment with bafilomycin A1 (Figure 8).
Furthermore, this restoration occurred both in the
absence and presence of Vpu. These findings suggest
that both of the detrimental effects of lentiviral vectors
on the GaLV Env are attributable to lysosomal
degradation.
Discussion
The ability of both retroviral and lentiviral vector parti-
cles to incorporate heterologous fusion proteins has
been extensively exploited in the development of gene
therapy vector systems [reviewed in [4] and [5]], as well
as in studies of fusion proteins from biohazardous
viruses [35-37]. Despite the general permissiveness of
retroviral particles to accommodate unrelated fusion
proteins, several examples exist where a lack of compat-
ibility between vectors and fusion proteins occurs
[12,13,38]. We have previously reported on the inability
of the GaLV Env protein to pseudotype HIV-1 derived
lentiviral vectors, where we observed a severe reduction
in the levels of the mature GaLV TM subunit in cell
lysates in the presence of lentiviral packaging plasmids
[13]. In the present study we further investigated the
basis for these reduced levels and identified a key role
for the HIV-1 Vpu protein in this event. Studies using
mutagenesis of both Vpu and GaLV Env, together with
results obtained using chemical inhibitors of cellular
degradation pathways, suggested a ubiquitin-dependent
targeting of GaLV Env to lysosomal degradation, occur-
ring at a stage in GaLV Env trafficking that is at, or
beyond, the trans-Golgi network.
Figure 5 Representative Western blot and quantitative analysis of signal density on blots from three independent experiments
analyzing GaLV TM levels in lysates of 293T cells co-transfected with GaLV Env, pHR’ and the indicated packaging plasmids. (SN)
indicates Vpu containing substitutions S52N and S56N. Immunological detection of HIV-1 p24 and cellular actin levels were included as controls.
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The HIV-1 Vpu protein is known to have several dif-
ferent activities [39]. Its cytoplasmic tail contains a
canonical DSGXXS destruction motif that recruits b-
TrCP, a component of the SCF E3 ubiquitin ligase com-
plex, and thereby mediates the degradation of at least
two host cell proteins, CD4 and BST-2/tetherin
[18,20-22]. Simultaneous binding of Vpu to the cytoplas-
mic tail of CD4 and the SCF ubiquitin ligase complex
targets the protein for proteasomal degradation [40-43],
while the downregulation of BST-2/tetherin, has been
suggested to involve either proteasomal [23] or lysoso-
mal [21,22] pathways.
Binding of Vpu to b- TrCP is critically dependent on
the phosphorylation of the two conserved serines, S52
and S56, in the DSGXXS motif [15,16]. We found that
these residues were also essential for Vpu’s activity
against the GaLV Env, suggesting that a similar b-
TrCP-dependent mechanism is involved. Vpu targeted
the GaLV Env at a stage after cleavage of the Env pre-
cursor, Pr85, into SU and TM subunits, suggesting that
the site of action was the trans-Golgi network or
beyond. Lastly, we showed that Vpu-mediated degrada-
tion of GaLV Env was achieved through the lysosomal,
not proteasomal pathway.
In addition, we observed that the substitution K618R
in the GaLV Env cytoplasmic tail completely blocked
the Vpu-dependent effect on TM levels. Although this
could suggest a role for ubiquitination at this lysine resi-
due, the K618Q substitution resulted in only a partially
rescued phenotype; thus, ubiquitination at this specific
residue may not be essential for the effect.
In addition to the strong phenotype associated with
the presence or absence of the Vpu protein, our study
also revealed that more than one level of incompatibil-
ity exists between lentiviral vectors and GaLV Env.
Even when Vpu was not expressed, lentiviral vectors
resulting from the co-expression of GaLV Env and
R8.91 incorporated only very low levels of Env, with
no detectable cleavage of the R-peptide observed, and
the resulting titers were extremely low. Other exam-
ples of incompatibility between Envs and particles have
been described within the Retroviridae, including a
block to incorporation of the Env protein from feline
endogenous virus RD114 into lentiviral vectors based
on simian immunodeficiency virus (SIV) [38], which
was suggested to be caused by a lack of Gag-Env inter-
action/co-localization [44,45]. Although beyond the
scope of this study, it will be interesting to determine
if such a mismatch in Env-Gag interaction and/or loca-
lization underlies the low-level incorporation and titers
observed for GaLV Env pseudotyped lentiviral vectors
based on R8.91.
Figure 6 Western blot and quantitative analysis of GaLV TM levels for wild-type and mutant versions of GaLV Env in the presence of
pHR’ and either control plasmid pGEM, or plasmids R8.2 or R8.91. Graphs indicate relative levels of GaLV TM compared to the pGEM
control, shown as the mean of 3-5 independent experiments. p-values were calculated, and statistical significance (p < 0.05) is indicated by an
asterisk. HIV-1 p24 immunological detection was included as control.
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An especially interesting aspect of this study was the
finding that Vpu alone was not sufficient to degrade
GaLV Env and block its incorporation into lentiviral
vectors, but this observation additionally required the
presence of one or more of the HIV-1 proteins present
on R8.91 (Gag-Pol, Tat, Rev) and to an even greater
extent in R8.2ΔVpu (additionally expresses Vif, Vpr
and Nef). Several possible mechanisms can be envi-
sioned to explain these requirements. First, Vpu itself
could be altered in some way by the presence of
another HIV-1 component, either directly or indirectly,
and this modification could be required to target the
GaLV Env. Alternatively, the ability of Vpu to target
GaLV Env may require a co-localization of the two
proteins, in a manner that could be promoted by the
assembly and/or budding of HIV-1 particles in the
same cell. Such a mechanism could involve either
recruitment of Vpu to sites where the GaLV Env is
also present or, alternatively, the recruitment of the
GaLV Env to sites where it becomes Vpu-accessible.
Targeting of the CD4 receptor by Vpu occurs in the
ER [46], while Vpu appears to target BST-2/tetherin in
the late endosomes [22]. Our data suggest that since
only the steady-state levels of SU and TM, and not
Pr85, were decreased, Vpu is likely to target GaLV Env
at or beyond the stage of Pr85 cleavage by furin in the
trans-Golgi network. It is also possible that Vpu inter-
feres with transport of Pr85 through the ER and Golgi
compartments, although such an effect would be
expected to result in the intracellular accumulation of
Figure 7 Analyses of levels of GaLV Env Pr85 precursor and SU subunit. A. Schematic representation of FLAG-tagged GaLV Env, showing
precursor (Pr85), mature SU and TM subunits, signal peptide (SP) and R peptide (R). B. Representative Western blots and quantitative analysis of
ratio of levels of FLAG-tagged GaLV Env Pr85 precursor and SU subunit, in presence of pHR’ and either control plasmid pGEM, or packaging
plasmids R8.2, R8.91 or R8.2ΔVpu. Samples were deglycosylated with either PGNase F or endoH prior to SDS-PAGE, and analyzed by
immunoblotting with anti-FLAG antibody.
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Pr85, and perhaps the 95 kDa intermediate, which we
did not observe.
Since the reduction in GaLV TM levels caused by
R8.2, or the co-expression of R8.2ΔVpu plus Vpu in
trans, was consistently greater than that achieved with
R8.91 plus Vpu in trans, the involvement of another
HIV-1 accessory protein in the overall effect on the
GaLV Env is also indicated. Indeed, a role for the HIV-1
Nef protein was suggested by the small but consistent
differences in activity for R82ΔNef compared to R8.2,
although the lack of statistical significance requires cau-
tion in the interpretation of these data. It has been pre-
viously shown that expression of Nef re-directs the
RD114 Env to late endosomes [45]. Since Vpu has been
shown to target BST-2/tetherin in late endosomes [22],
it is possible that a minor cooperative effect exists
between these two HIV-1 accessory proteins. Alterna-
tively, since Nef has previously been shown to mediate
the endocytosis and rapid degradation of cell surface
CD4 in lysosomes [47,48], it is also possible that a
minor part of the effect seen on GaLV Env levels could
be directly attributable to a similar activity of Nef.
Conclusions
The destabilization of the GaLV Env protein that occurs
in the presence of lentiviral vector components is mostly
attributable to the action of the HIV-1 Vpu protein. Our
data suggest that this event involves the recruitment of
the SCF E3 ubiquitin ligase complex and the targeting
of protein for lysosomal degradation, as previously
demonstrated for BST-2/tetherin down-modulation by
Vpu. However, degradation of the GaLV Env by Vpu is
a distinct event in that it additionally requires the pre-
sence of other, as yet unidentified, HIV-1 components.
Although the exact mechanism involved is not yet clear,
these observations suggest that a more complex interac-
tion may exist between Vpu and its target proteins, that
is regulated by some other aspect of HIV-1 replication,
and which provide an extra level of control that has not
previously been appreciated. Since HIV-1 and GaLV do
not infect the same hosts, it is most likely that this tar-
geting of the GaLV Env by HIV-1 reflects some essential
similarity in the GaLV Env protein to other host or viral
proteins that are bona fide targets of Vpu’s activity.
Materials and methods
Cell lines
Human kidney epithelial 293T cells (ATCC, Manassas,
VA) were maintained in D10, Dulbecco’s modified
Eagle’s medium (Mediatech, Herndon, VA) supplemen-
ted with 10% fetal bovine serum (Hyclone, Logan, UT)
and 2 mM glutamine (Gemini Bio-Products, West
Sacramento, CA).
Plasmids
All GaLV Env proteins were based on the SEATO strain
(Genbank: NP056791) and expressed from plasmids
containing the human cytomegalovirus (CMV) immedi-
ate early promoter. Construct GM(TR) is a GaLV Env
containing the cytoplasmic tail of the amphotropic MLV
Env and has been described previously [13]. The GaLV
Env mutants K618R and K618Q were generated by
PCR-directed mutagenesis. The FGaLV Env construct
was generated by substituting the 5’-terminal sequence
of GaLV Env ORF in our expression plasmid by that of
the FLAG-tagged FGaLV.fus [49], kindly donated by Dr
Adele Fielding. Retroviral packaging plasmid pCgp that
expresses MLV Gag-Pol, and transfer vector pCnBg,
have been described previously [50]. HIV-1 packaging
constructs pCMVΔR8.2 and pCMVΔR8.91 (herein
abbreviated as R8.2 and R8.91) and transfer vector
pHR’-CMVLacZ have been described previously
[1,25,51]. Constructs R8.2ΔVpu, R8.2ΔVifΔVpr and
R8.2ΔNef were created as chimeras between R8.2 and
R8.91 by inserting SalI- BamHI, SwaI-SalI and BamHI-
XbaI fragments, respectively, from R8.2 into R8.91. Plas-
mid R8.91Vpu was created by insertion of BamHI-SalI
fragment from R8.2 into R8.91. Constructs R8.2Vpu(SN)
and R8.91(SN) contain S to N substitutions at residues
52 and 56 in the Vpu protein and were created by PCR
mutagenesis The CΔEVpu vector expresses Vpu under
the control of the CMV promoter, and the parental
expression plasmid CΔE (no ORF) was used as a control
plasmid to ensure equivalent levels of DNA in
transfections.
Figure 8 Representative Western blots of levels of FLAG-
tagged GaLV Env Pr85 precursor and SU subunit in presence
of pHR’ and either control plasmid pGEM (Ctrl.), R8.2 or
R8.2ΔVpu. Cells were treated with either the proteasomal inhibitor
MG132, the lysosomal inhibitor bafilomycin A1, or DMSO. Samples
were deglycosylated using endoH prior to SDS-PAGE, and analyzed
by immunoblotting with anti-FLAG antibody.
Christodoulopoulos et al. Retrovirology 2010, 7:4
http://www.retrovirology.com/content/7/1/4
Page 10 of 12
Production of retroviral and lentiviral vectors
Retroviral vectors were generated by the co-transfection
of plasmids pCgp, pCnBg and a plasmid encoding an
appropriate GaLV Env protein into 293T cells, essen-
tially as described [13,50], with culture supernatants
containing vector particles harvested 24 hours post
transfection. Lentiviral vectors were generated in the
same way using packaging plasmids R8.2 or R8.91 and
in the presence of transfer genome plasmid pHR’-
CMVLacZ [13,50]. Control transfections included
equivalent amounts of cloning vector plasmid pGEM
(Promega, Madison, WI).
Western blotting of viral vector particles
Vector particles were harvested from the supernatants of
transiently transfected 293T cells and partially purified
by centrifugation through 2 ml of 20% sucrose at 75,000
× g. at 4°C for 2 hours. Cell monolayers of transfected
293T cells were incubated in 200 μl lysis buffer (20 mM
Tris-HCl, pH 7.5, 1% triton X-100, 0.05% SDS, 5 mg/ml
sodium deoxycholate, 150 mM NaCl, and 1 mM phenyl-
methanesulphonylfluoride) for 10 min at 4°C, followed
by centrifugation at 10,000 × g for 10 minutes to pellet
cell debris. All protein samples were normalized for
equal protein concentration using the Bradford assay
(Biorad, Hercules, CA) prior to electrophoresis and
Western blotting. The transmembrane (TM) subunit of
the GaLV Env was detected with rat monoclonal anti-
body 42/114 [52]. Vpu was detected with the HIV-1NL4-
3 Vpu antiserum [53], p24 with the HIV-1SF2 p24 rabbit
antiserum, both obtained through the AIDS Research
and Reference Reagent Program, Division of AIDS,
NIAID, NIH. FLAG-tagged GaLV Env protein was
detected using mouse M2 anti-FLAG antibody (Sigma,
St Louis, MO). Actin was detected using anti-actin
monoclonal antibody (clone C4, Roche Applied Science,
Indianapolis, IN), and MuLV p30 using the goat anti-
Rauscher MLV CA antiserum (Quality Biotech, Camden,
NJ).
Analysis of glycosylated proteins
Fifteen μl of cell lysates were heated at 95°C for 5 min-
utes, in peptide N-Glycosidase F (PNGaseF) denatura-
tion buffer, followed by the addition of 1× G7 buffer, 1%
NP40 and 500 U PNGaseF (NEB, Ipswich, MA), and
samples were incubated at 37°C for 1 hour. Alterna-
tively, 15 μl of cell lysates were heated at 100°C for 10
minutes in 1× endoglycosidase H (endoH) denaturation
buffer, followed by the addition of 1× G5 buffer and 500
U of endoH (NEB, Ipswich, MA), and samples incubated
at 37°C for 1 hour. Treated lysates were resolved by
SDS-PAGE, followed by Western blotting using anti-
FLAG antibody.
Inhibitor studies
Proteasomal or lysosomal degradation pathways were
inhibited by incubation with MG132 and bafilomycin
A1 (Sigma, St Louis, MO) at concentrations of 10 μM
and 100 nM respectively, for 8 hours.
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